Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GamLPV Phase I Study in Healthy Volunteers
NCT03137927Phase 1Completed
- Start
- Jun 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of lopinavir + ritonavir in pertussis (6 arms). Primary endpoint: Safety and Tolerability at 150 days. Started Jun 2017; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT03137927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03137927.